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Dummy runa b s t r a c t
Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment
for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachyther-
apy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study
were to evaluate vaginal brachytherapy quality and protocol adherence.
Methods: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-
scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly
selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans
according to a checklist.
Results: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning.
After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to
99.9% and range and standard deviation (SD) narrowed from 83.6–135.1 to 96.4–101.4 and 8.8 to 1.1,
respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27
(18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex
(98.0%, 74.7–114.2, SD 7.6) or reference volume length.
Conclusions: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial
was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality
assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in
all participating institutes.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 155 (2021) 160–166 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).The primary treatment for women with endometrial cancer (EC)
is abdominal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy, followed by adjuvant radiotherapy depending on
clinicopathological risk factors. Currently, four risk groups of EC
have been defined: low, intermediate, high-intermediate (HIR)
and high-risk [1].
For women with HIR EC the standard adjuvant treatment is
vaginal brachytherapy (VBT), which is based on previous ran-
domised trials. VBT was shown to be equally effective compared
to external beam radiotherapy (EBRT) in local control and survival,
with a markedly lower toxicity profile [2–6]. However, there is still
considerable overtreatment, as approximately 7–10 women with
B.G. Wortman, E. Astreinidou, M.S. Laman et al. Radiotherapy and Oncology 155 (2021) 160–166HIR EC need to be treated with adjuvant VBT to prevent one recur-
rence [7]. Better selection of patients at risk of recurrence may play
an important role in reducing overtreatment.
The Cancer Genome Atlas Group (TCGA) has discovered four
specific molecular subgroups of EC, with each subgroup having a
distinct prognosis [8]. Using surrogate markers, these molecular
subgroups have been validated in independent EC cohorts and
have been shown promising in guiding decisions on adjuvant treat-
ment [9–12]. The role of molecular factors in decision making on
adjuvant treatment of HIR EC is currently being investigated in
the ongoing international randomised PORTEC-4a trial [13]. In this
trial, women with HIR EC are stratified in a favourable, intermedi-
ate or unfavourable profile based on molecular and clinicopatho-
logic risk factors and consequently treated with no adjuvant
treatment, VBT or EBRT, respectively [14].
In view of the use of VBT in the standard arm and for the
women with intermediate profile in the experimental arm, approx-
imately 60% of the PORTEC-4a trial population will receive VBT, a
single channel brachytherapy plan using a vaginal cylinder. The
VBT planning is based on delineation of the target volume and
organs at risk on CT- or MRI-images during at least one fraction.
Imaging with CT or MRI with a vaginal cylinder in situ can provide
valuable data on dose distribution to the target volume and rectum
and bladder that can be used for evaluation of VBT related toxicity.
Since institutes had limited experience with delineating on CT- or
MRI-scans for single channel VBT, and to ensure uniform high-
quality brachytherapy in the PORTEC-4a trial, a dedicated VBT
quality assurance (QA) programme, including a dummy run proce-
dure, was implemented in the trial. Especially for radiotherapy tri-
als in general, QA is considered essential as a decrease in
therapeutic effectiveness and impaired trial outcomes by protocol
deviations have been reported [15,16]. Furthermore, QA increases
trial protocol adherence and treatment uniformity, and therewith
ensures optimal treatment in both arms which leads to more reli-
able trial outcomes [17–23].
The aim of the current study was to investigate protocol adher-
ence by evaluating results of the dummy run procedure and three
annual QA rounds in the international PORTEC-4a trial.Methods
Trial objective
The main objective of the randomised PORTEC-4a trial is to
evaluate adjuvant treatment directed by molecular-integrated risk
profiles for women with HIR EC, defined as: either (1) FIGO stage IA
(with invasion) and grade 3; (2) FIGO stage IB grade 1 or 2 with age
60 and/or LVSI; (3) FIGO stage IB grade 3 without LVSI; or (4)
FIGO stage II (microscopic) and grade 1. Based on three risk pro-
files, women in the experimental arm will receive either no further
treatment when favourable, adjuvant VBT when intermediate, or
EBRT when unfavourable. Women randomised to the standard
arm receive adjuvant VBT. Details on patient selection, treatment
and trial logistics have been published previously [13,14].
Trial registration numbers – clinicaltrials.gov (NCT03469674);
ISRCTN11659025; NTR5841.Vaginal brachytherapy in the PORTEC-4a trial
Vaginal brachytherapy should start within 6–8 weeks from the
date of surgery. High dose rate (HDR) brachytherapy is given with a
vaginal cylinder with one active central channel. Prior to cylinder
insertion vaginal examination should take place to verify if the sur-
gical scar has healed sufficiently. Preferably the cylinder with the
largest diameter that fits comfortably is used to ensure optimal
contact with the vaginal mucosa, resulting in an optimal dose gra-161dient at the surface. After the cylinder placement, correction to a
horizontal position is recommended to avoid unnecessary dose to
the rectum or bladder [24].
At the first brachytherapy session a CT- or MRI-scan with the
applicator in situ is made for delineation of the CTV and organs-
at-risk (OARs) and treatment planning. The CTV consists of the
vaginal wall and apex of the upper 1/3 of the vagina; for the major-
ity of patients this corresponds to a length of approximately
3.5 cm. The CTV is delineated as a ring structure that surrounds
the applicator with a 3 mm margin. OAR include the bladder, rec-
tum, sigmoid and small bowel (loops).
For treatment planning, a library of standard plans per applica-
tor type, diameter and target length are used, with 6 dose reference
points, A1 to A6 (Fig. 1). Points A1 and A3 are located at the top of
the cylinder at 5 mm from the cylinder surface, with A1 at the cen-
tral axis and A3 5 mm laterally from A1. Parallel to the central axis
at 5 mm from the cylinder surface points A2 and A4 to A6 are
placed. A2 is located halfway along the length of the active dwell
positions, A4 at the first possible dwell position and point A5 and
A6 in between A4 and A2 and caudal of A2, respectively (Fig. 1).
Three fractions of 7 gray (Gy), prescribed to dose point A2,
should be delivered within an overall treatment time of 2 weeks.
To ensure an adequate dose in the apical vaginal mucosa and com-
pensate for the anisotropy in the longitudinal direction of the 192-
Iridium source, the dose in point A1 should be at least 90% and in
A3 110% at maximum, with an average dose in A1 and A3 of 100%
(7 Gy). A symmetrical loading pattern of the cylinder in the cranial-
caudal direction is recommended to facilitate treatment planning,
but not mandatory. The reference volume length (RVL) represents
the length of the vaginal wall that receives 100% or more and is
measured from the top of the 100% isodose line to the point where
it enters the cylinder caudally. The RVL should be around 40–
45 mm, with a maximum of 50 mm, ensuring sparing of the lower
vaginal wall. The mean doses to 90% and 98% of the CTV (D90 and
D98) and the maximum dose to 2 cc (D2cc) of the OARs, should be
recorded.Brachytherapy QA-procedure
Dummy run procedure
Before site activation, all participating institutes must have
filled in a pre-trial credentialing questionnaire and have performed
a dummy run procedure. The questionnaire addresses items such
as imaging modality, type of afterloader, cylinder and treatment
planning software (TPS) and VBT staff. For the dummy run
DICOM-images of a pelvic CT and MR scan with a cylinder in situ
are sent to each institute. The local brachytherapy teams are
requested to delineate the CTV and OAR conforming to the trial
protocol, and to create a brachytherapy plan by using their own
TPS. This plan is evaluated by a central QA-panel consisting of
two radiation oncologists and one medical physicist specialised
in brachytherapy (R.A.N.; C.L.C.; E.A.), a radiation oncologist in
training (B.G.W.) and an advanced practitioner brachytherapy (M.
S.L.). In case of protocol deviations feedback is sent and the dummy
run procedure is repeated when necessary. Upon successful com-
pletion of the dummy run procedure, institutes can be activated
for the trial.Annual quality assurance
Annual QA consists of evaluation of a VBT plan of one randomly
selected PORTEC-4a case number that has received VBT in the trial
in the specific centre. The local team is asked to provide the anon-
ymised CT- or MRI-scan that was used for VBT planning, the
DICOM RT-structures, planning and dose distribution, including
dose to the A-points, OARs and CTV. Alongside the DICOM-data,
Fig. 1. Dose distribution for a vaginal cylinder diameter 3.5 cm. 100% isodose line
(red). Dose is specified to point A2; average dose of A1 + A3 should be
approximately 100%; dose to A1 > 90% and A3 < 110%; A4–6 aim for dose reporting
with the aiming to reach >95%. Reference length/width (dotted arrows), reference
length should aim for 40–45 mm, with a maximum of 50 mm.
Quality assurance for vaginal brachytherapy in the PORTEC-4a trialupdated credentialing questionnaires are requested to objectify
changes in VBT components or staff. All requested data, images
and plans were evaluated by the QA-panel.Table 1
















According to a QA-checklist all plans of both the dummy run
and annual QA were scored on delineation, treatment planning
and dose distribution. Annual QA was additionally scored on appli-
cator positioning. Results for each of the items were categorised as
fully compliant, partly compliant, in case of a minor protocol devi-
ation, or not compliant, in case of a major deviation. When one or
multiple items were scored as partly or not compliant at the
dummy run, a revised VBT plan was requested and evaluated. In
case of major deviations at annual QA, a teleconference was held
for additional explanation and discussion of the feedback, and
the next new case number of that particular institute was
requested for an extra QA.
On all received data of both the dummy run and the three
annual QA procedures descriptive analyses were performed for
evaluation of protocol compliance, by comparing the first and final
dummy run plan and the annual QA, for the following dose param-
eters: mean percentage dose, with 100% being 7 Gy, the dose range
and standard deviations of all A-points, D98 and D90 of the CTV
and the D2cc of the OARs.
To estimate the influence of inter-observer delineation variation
on the dose parameters, all delineated structures of the accepted
plan of dummy run were projected on the dummy run CT-scan
with the LUMC applicator reconstruction and LUMC dose plan. This
resulted in the same dose distributions for each case, but variating162delineations of the CTV and OARs. For this sub-analysis the mean
dose, dose range and standard deviation were recorded. The two
institutes with MRI were not included in this analysis.Results
Between June 1st, 2016 and March 30th, 2020, 327 patients
have been included in the PORTEC-4a trial in 19 institutes in 5
countries. Currently, 21 institutes have successfully completed
the dummy run. For the dummy run, 19 institutes used CT for
brachytherapy planning and two MRI. Three different types of
treatment planning systems and three different HDR afterloaders
are used (Table 1). Institutes reported the use of several types of
single channel vaginal applicators, varying from standard applica-
tors produced by Elekta or Varian, to dedicated applicators, pro-
duced in their own institution.
In total, 21 institutes successfully completed the dummy run
procedure and participate in the PORTEC-4a trial. Six out of 21
(28.6%) VBT plans were accepted after the first run, 15 (71.4%)
needed to resubmit for minor or major adjustments. Common
aspects for revisions were: CTV or OAR delineation (Fig. 2A and
B), dose planning (Fig. 2C–E) and applicator reconstruction. After
adjusting delineation of the CTV and/or dose planning of the VBT
plans, the mean dose in the dose prescription point (A2) decreased
from 101.5% to 100.5% of the prescribed dose, with 7 Gy being
100%, and the range and standard deviation (SD) of the mean nar-
rowed from 100.0–109.7% to 99.5–105.4% and 2.9 to 1.3, respec-
tively. For the dose at the vaginal apex (mean dose in A1 + A3)
the mean decreased from 100.7% to 99.9%, the range from 83.6–
135.1% to 96.4–101.4%, and the SD from 8.8 to 1.1 (Table 2). In
table 3 the effect of inter-observer delineation variation on the
dose parameters is displayed.
Three annual QA rounds have been performed between
September 2017 and February 2020, for which 7, 13 and 7 VBT
plans were evaluated in the first, second and in the first part of
the third round, respectively. Of 27 requested VBT plans, 22
(81.5%) were accepted with no or minor feedback, while for five
(18.5%) plans a teleconference was held for discussion of the feed-
back, and a new VBT plan of a subsequent case was requested.
Most common items for feedback were: CTV delineation (n = 16;
CTV length longer than 4.0 cm, or not delineated as a ring struc-
ture, or with a margin of more than 3 mm), average dose in points
A1 and A3 other than 100% (n = 13; 5 partly (100% ± 3%) and 8 not
compliant (100% ± >3%), see Fig. 2C and D), and RVL of more than
50 mm (n = 19, see Fig. 2E and F). Other feedback items addressed
applicator positioning (n = 8), suboptimal contact with the vaginal
mucosa (n = 5; air or contrast surrounding the applicator), and
delineation of the OAR (n = 10, see Table 4).
Fig. 2. Most common reasons for feedback. Delineation: organs at risk and CTV (A). CTV should be a ring structure surrounding the applicator and all bowel loops should be
included (B). Treatment planning: Mean dose in point A1 + A3 (C) should be 100% (D) and reference volume length (E) should be around 40–45 mm (F).
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The mean dose in the dose prescription point (A2) was 100.4%
(range 99.0–108.7%, SD 1.7), and at the vaginal apex (mean
A1 + A3) 98.0% (range 74.7–114.2%, SD 7.6). The mean RVL was
53.8 mm, ranging from 44.3 to 70.0 mm. Mean D90 and D98,
respectively, of the CTV were 7.9–8.0 Gy and 7.2–7.3 Gy, respec-
tively, in both the dummy run and the annual QA rounds. The
mean D2cc of the rectum ranged from 6.0 to 6.1 Gy in both dummy
run and QA, and the mean D2cc of the bladder, sigmoid and small
bowel varied from 5.2 to 5.9 Gy, 2.9 to 3.7 Gy and 2.8 to 5.5 Gy,
respectively (Table 2).
Several changes have been observed in the QA-questionnaires:
two institutes changed to a different cylinder applicator, two to
another type of afterloader, and three institutes changed their
TPS. In five institutes there was a change of brachytherapy staff;163two medical physicists and three radiation oncologists were
replaced.
Discussion
Analysis of the dummy run procedure for vaginal brachyther-
apy in the PORTEC-4a trial showed that 71.4% of the initially sub-
mitted VBT plans needed adjustments to fulfil trial protocol
requirements. With the revised VBT plans, an increase in protocol
adherence and a decrease in inter-observer delineation and/or dose
planning variability were observed, which resulted in more uni-
form VBT plans. Evaluation of the annual QA of randomly selected
VBT plans per centre showed that 18.5% had major protocol devi-
ations, suggesting that a successful dummy run procedure does
not rule out major protocol deviations during the trial.
Table 2




plan* (N = 21)
Dummy run final






101.5 (2.9) 100.5 (1.3) 100.4 (1.7)





93.1 (8.8) 92.0 (1.7) 90.2 (7.0)





108.2 (9.0) 107.8 (1.8) 105.7 (8.4)
Range 91.3–143.4 102.5–110.0 81.7–125.5




100.7 (8.8) 99.9 (1.1) 98.0 (7.6)




83.2 (7.1) 84.9 (6.9) 87.1 (6.2)





96.4 (3.2) 96.8 (3.7) 98.5 (2.9)





97.3 (3.2) 96.9 (3.1) 98.7 (3.5)
Range 88.9–102.1 88.9–102.1 87.6–104.6
D90***
Mean (SD) 7.9 (0.8) 8.0 (0.9) 8.0 (0.9)
Range 6.3–9.4 6.3–9.4 5.6–9.7
D98
Mean (SD) 7.2 (0.9) 7.3 (0.9) 7.3 (1.2)
Range 5.1–8.6 5.8–8.6 4.0–9.2
Bladder D2cc
Mean (SD) 5.2 (0.5) 5.3 (0.5) 5.9 (0.8)
Range 4.3–6.0 4.3–6.0 4.8–7.7
Rectum D2cc
Mean (SD) 6.1 (0.5) 6.1 (0.5) 6.0 (0.6)
Range 4.7–7.1 5.0–6.9 4.0–7.2
Sigmoid D2cc
Mean (SD) 3.7 (1.2) 3.6 (1.2) 2.9 (1.2)
Range 2.1–6.9 1.4–6.4 0.5–5.1
Small bowel
D2cc
Mean (SD) 5.5 (1.6) 5.3 (1.8) 2.8 (1.8)
Range 1.1–7.8 0.9–7.3 0.8–6.9
* Institutes for which the first dummy run plan was accepted have been listed in
both columns (N = 6)
** Mean percentage dose, with 100% being 7 Gy.
*** Dose in Gy.
Table 3
Variation in dose parameters resulting from inter-observer differences in delineation
at the dummy run.
Dose parameter Mean*(SD) Range
CTV D90 8.1 (0.5) 7.4–9.2
CTV D98 7.3 (0.6) 6.3–8.4
Rectum D2cc 5.9 (0.5) 4.7–6.8
Bladder D2cc 5.0 (0.6) 4.4–5.6
Sigmoid D2cc 3.5 (0.9) 2.1–6.1
Small bowel D2cc 5.6 (0.8) 4.1–6.8
* Dose in Gy.
Table 4








Position and angle of cylinder 19 2 6




CTV delineation 11 11 5
OAR delineation 17 8 2
Treatment planning
Reconstruction 24 1 2
Position of A points 20 3 4
Prescribed dose in point A2 22 3 2
Symmetry of loading pattern 18 0 9
Evaluation of dose distribution
Average dose in A1 + A3 = 100% 14 5 8
Dose in point A1  90% and/or
A3  110%
17 6 4
Reference length/width 8 15 4
CTV D90/D98 19 1 7
OAR D2cm3 24 3 0
* Scored according to the detailed description in the trial protocol.
Quality assurance for vaginal brachytherapy in the PORTEC-4a trialIn this quality assurance study, most common reasons for feed-
back were delineation of the CTV and OAR, the average dose at the
vaginal apex (dose points A1 + A3) and the reference volume
length (RVL). Dose points A1 and A3 represent the vaginal vault
area which is essential for the target volume. These dose points
are aimed to obtain a uniform and reproducible dose distribution
at 5 mm from the apex, even with use of different types of cylin-
ders, sources and treatment planning systems in a randomised
multicentre trial. The dose at the apex is essential, not only because164approximately over 75% of all recurrences occur at the vaginal
apex, but also because a higher dose in point A3 could lead to
increased toxicity due to the adjacent bowel loops [25–27]. The
RVL directly displays the actual length of the vaginal wall receiving
100% of the dose. The mean RVL in this study was 53.8 mm, while
when following the trial protocol, the RVL should range between
40 and 50 mm. In case of an increased RVL, a longer segment of
the vagina receives significant dose. This observation led to a gen-
eral feedback to make all participating institutes aware of this and
re-emphasise the importance of the trial planning aims.
Minor feedback items addressed the applicator placement and
applicator diameter. When the applicator was placed ventrally or
dorsally this could lead to higher doses to the bladder or rectum
[24]. In 5 out of 27 reviewed cases the diameter of the vaginal
applicator seemed relatively small and air gaps or contrast sur-
rounded the applicator, directly affecting the dose distribution.
A previous study showed an average dose reduction to the vagi-
nal mucosa of 27% when air gaps were present and stressed that
air gaps of more than 2 mm can lead to a decrease in dose to
the vaginal mucosa, which in turn may result in an increased
risk of local recurrence. Institutes were provided feedback to
ensure that an attempt is made to reposition the applicator or
to use a larger diameter applicator for more optimal contact to
the vaginal mucosa. However, the presence of air gaps has not
been related to clinical outcome, as a wide range of dose and
fractionation schedules for VBT has been proven effective
[28–31].
Data of dose parameters showed improvements in the dose
range between the first and the final plan of the dummy run
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the increased protocol adherence. However, at annual QA, one or
more years after the initial dummy run, an increased variability
in dose distribution and in dose to points A1, A2, A3 and A6 was
observed, also at institutes with a large case load. Possible explana-
tions for this could be institutional changes in type of applicator,
afterloader, TPS or VBT staff, that were recorded in the question-
naires; adherence to a local VBT protocol; unfamiliarity with CTV
delineation for single channel VBT or unfamiliarity with the trial
protocol due to infrequent inclusion. This indicates that continuous
QA is essential to ensure protocol adherence in the years after the
initial dummy run.
The range and standard deviation of dose parameters D90
and D98 of the CTV and D2cc of the OAR remained similar in
the first and final plan of the dummy run, even after adjust-
ments of the delineation and/or VBT planning. This could be
explained by the impact of delineation variations on these
parameters. Additional analysis showed that when eliminating
treatment planning variation, by projecting delineations of all
institutes on one standard VBT plan, similar standard deviations
and ranges were found for CTV D90/98 and D2cc of the OAR in
the accepted plans. This means that this remaining variability in
dose parameters is caused by inter-observer delineation varia-
tions and this should be taken into account when interpreting
dose parameter data. Contouring of organs at risk on MRI scans
would have been more precise than on CT-scans, but only a
minority of centres have MRI available for standard cylinder-
based brachytherapy.
Using a uniform protocol for VBT ensures high quality VBT
and is essential for increasing reliability of dose parameters that
can be used for evaluation of VBT related toxicity. A continuous
QA-programme in a multi-institutional radiotherapy trial can
increase treatment and delineation uniformity and which has
been shown to impact on trial outcomes [15,32]. A review on
QA for radiotherapy in randomised trials showed that major pro-
tocol deviations were observed in 11.0–48.0% of all cases, and
were reported to be associated with impaired overall survival
and local control and potentially increased treatment related
toxicity [15]. This has also been reported by several other inves-
tigators, emphasising that the design of the QA-procedure needs
to be tailored to specific trial techniques and outcomes
[20,22,23,32–34].
To our knowledge, this is the first study on dedicated QA for
single channel VBT with delineation on CT- or MRI-scans for
endometrial cancer. Our findings confirm that a dummy run
and QA-procedure in multi-institutional radiotherapy trials cre-
ates awareness of the trial protocol and principles and guideli-
nes of the specific treatment, improves protocol adherence and
quality of the treatment. Even after successful initial dummy
run procedures, annual QA showed major protocol deviations
in 18.5% of reviewed cases, suggesting that continuous annual
QA is essential to promote protocol adherence, ensuring uni-
form high-quality vaginal brachytherapy a multi-institutional
trial.Conflicts of interest
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